MariMed Q1 2025 Earnings Call Transcript

Quartr
Provided by Quartr
May 8, 2025

Key Takeaways

  • Meramec’s wholesale revenue grew 16% year-over-year, representing 44% of total revenue (up from 42%), as products were placed in 70 new dispensaries this quarter.
  • Total Q1 revenue was flat at $38 million year-over-year and decreased 2.7% sequentially, largely due to a soft retail quarter, resulting in a net loss of $5.4 million.
  • Non-GAAP adjusted gross margin fell to 41.3% from 43.8% a year ago, pressured by price compression and ramp-up costs for new cultivation and processing facilities.
  • Management plans to expand its brand footprint via M&A and licensing deals, targeting adult-use market entry in Delaware, New York, Missouri and other high-growth states.
  • The company is launching Microdose by Nature’s Heritage, a vegan, functional mushroom pill, and evaluating hemp-based product lines to diversify revenue beyond cannabis.
AI Generated. May Contain Errors.
Earnings Conference Call
MariMed Q1 2025
00:00 / 00:00

Transcript Sections

Skip to Participants
Operator

Good morning, my name is Konstantin, and I will be your conference operator today. At this time, I would like to welcome everyone to the MariMed Inc's First Quarter 2025 Financial Results conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during this time, simply press star then the number one on your telephone keypad. If you would like to withdraw your question, please press star then the number two. Thank you. I will now turn the line over to Mr. Kevin Compagna to begin the conference.

Kevin Compagna
Kevin Compagna
VP of North America Sales Wholesale and Licensing at MariMed Inc

Hello and good morning to you all. I'm Kevin Compagna, Head of Wholesale Sales at MariMed. I've been with MariMed for close to four years and joined the team after 20 years in beer and alcohol and various leadership roles. I'm very proud of the team that we've built and the success we've achieved in continually growing market share for all of our brands. I am honored to kick off today's first quarter earnings for 2025. Joining the call today are Jon Levine, our Chief Executive Officer; Mario Pinho, our Chief Financial Officer; and Ryan Crandall, our Chief Commercial Officer. This call will be archived on our investor relations website and contains forward-looking statements. Actual events or results may differ materially from these forward-looking statements and are subject to various risks and uncertainties.

Kevin Compagna
Kevin Compagna
VP of North America Sales Wholesale and Licensing at MariMed Inc

A discussion of some of these risks is in the risk factor section of our 10-K available on our website. Any forward-looking statements reflect management's expectations of today, and we assume no obligation to update them unless required by law. Additionally, we will refer to certain non-GAAP financial measures which are reconciled in our earnings release. I will now turn the call over to Jon for his first quarter overview.

Jon Levine
Jon Levine
CEO and President at MariMed Inc

Thank you, Kevin. For the hard work you and your team are doing to help us become a leading cannabis CPG company. Good morning, everyone. Thank you for joining us today. Last night, we reported our Q1 results. Our revenue for the quarter was essentially flat versus the same period last year, despite a dynamic environment. I continue to believe everything we're doing today to build a brand powerhouse will ultimately deliver the enhanced shareholder value our investors demand and deserve. Our brands continue to capture more share across the markets we serve, and we sold them into 70 new storefronts in the quarter. As a result, our wholesale revenue grew year over year sequentially and as a percentage of our overall business. Wholesale now accounts for 44% of our revenue mix, up from 42% sequentially.

Jon Levine
Jon Levine
CEO and President at MariMed Inc

That's been our strategy, and we expect to see the percentage continue to climb as we further leverage our brands as a primary growth engine for the company. Executing that plan to increase wholesale sales is resulting in short-term impact on our financial performance that I wanted to discuss. We've always said that the ultimate winners in cannabis will be the companies with the most trusted and best-selling brands. I'm very proud that we're well on the way towards that goal. We're confident that ultimately our strategy will pay off with similar gross margins of 45%+ like traditional CPG companies such as P&G or Coca-Cola. To get there, we need two things to happen. First, we need greater scale, both at wholesale and selectively at retail. That's our focus right now, and I'll share what we're doing in a minute to keep expanding our brand distribution.

Jon Levine
Jon Levine
CEO and President at MariMed Inc

Second, we need legislative reform that will enable significant operating efficiencies for companies like ours that will come with interstate commerce, e-commerce, and other benefits. In advance of these catalysts, our margins are likely to lag behind other MSOs for the simple reason that they have a much larger retail footprint. The way we see it, though, the pendulum is going to swing in the other direction. With our strong wholesale performance, we were able to partially offset a soft quarter at our retail stores. Pricing pressures across all markets, new competition in Illinois, and the general economic uncertainty all contributed. We're mitigating the impact through a series of pricing, marketing, cost reduction strategies to encourage more transactions, drive customer loyalty, and support margin expansion. Ryan will provide more detail in his remarks. We're confident these initiatives will pay off over the long term when consumers' confidence returns.

Jon Levine
Jon Levine
CEO and President at MariMed Inc

An area where we could not be prouder is how we are doing in supporting the people and the communities we serve. Our in-house brands, Help on the Home Front program, is a great example. Through the program, we raise visibility about the challenges our nation's veterans face in dealing with their housing costs. The issue has never been as important as right now, given the state of the economy. We are thrilled to award thousands of dollars to worthy veterans to help defray the cost of their home expenses, and we are looking to build on the program later this year. Speaking of the economy, let me spend a minute on tariffs and their impact on our business. For the short term, we should not see any significant impact. Beyond that, we are monitoring tariffs like everyone else in assessing in real time how to approach the rest of the year.

Jon Levine
Jon Levine
CEO and President at MariMed Inc

For example, we're looking at alternative suppliers for certain inputs and hardware. That's the discipline approach that has been the cornerstone of how we've always operated the business. It's what has allowed us to grow MariMed while maintaining a strong balance sheet. It's that same approach and our strong balance sheet that enable us to implement two key strategic initiatives that will fuel long-term growth and profitability. The first is what I call expand the brand, which involves continuing to make our brands accessible to as many people as we can in both existing markets and new markets. It starts with investing in innovation to create additional new products that meet the needs of today's increasingly sophisticated cannabis consumer. Ryan is going to share details of a product we're launching in the next few weeks, and we're very excited about it. Creating the product is half the battle.

Jon Levine
Jon Levine
CEO and President at MariMed Inc

The other half is selling it. Our brands are already top sellers, but there's significant opportunity to seize additional share. We believe that more effectively aligned sales marketing operations will help us make it happen. Ryan's recent all well-deserved promotion to Chief Commercial Officer is a key to that effort. As far as new markets are concerned, we continue to be in M&A discussions with a number of operators to acquire assets that would enable us to immediately and profitably distribute our brands in new high-growth states. We're making meaningful progress, and I'm hopeful we'll have something more definitive to share in the months to come. The goal of any acquisition is to integrate the operation as seamlessly as we have with First State Compassion in Delaware. We completed that transaction on March 1st.

Jon Levine
Jon Levine
CEO and President at MariMed Inc

Our teams have been working together as we get ready for adult use sales, which we expect to commence this year. We're also looking to enter new markets through licensing opportunities. We have been negotiating with potential partners in several states where we're confident our brands can capture significant market share. The second initiative we're focused on to fuel our long-term growth and profitability involves identifying new sources of revenue. We can't just keep waiting for the federal government to help our industry anymore. We know reform will happen eventually, but eventually is not a growth strategy. We're taking charge. Our team is assessing our best options to enter the hemp space. With our strong brand recognition and performance, consumers throughout the country tell us they like to buy our products in their states.

Jon Levine
Jon Levine
CEO and President at MariMed Inc

We believe entering the hemp space will help us generate new revenue while staying focused on our strategy of expanding our brand distribution into new storefronts. The key for us will be to make it happen without taking the eye off the ball of our core business. I will now turn the call over to Ryan for his update.

Ryan Crandall
Ryan Crandall
Chief Commercial Officer at MariMed Inc

Thanks, Jon, and good morning, everyone. As Jon said, wholesale penetration and the power of our brands continue to be the lead story for us. On our last earnings call, we said our brands are the moat surrounding our business. The moat got a little wider during the first quarter. Let me give you some highlights. Missouri is off to a very nice start for us with Betty's, Bubby's, and Vibations entering the quarter in nearly 50 storefronts. Reciprocity is a real challenge in that market. Without any dispensaries of our own to buy our customers' products, it has been the incredible reputation of our brands that opened doors for us. In Illinois, we sold our products into more than 180 stores during the quarter, which was a 5% increase sequentially and 46% year on year.

Ryan Crandall
Ryan Crandall
Chief Commercial Officer at MariMed Inc

All of the brands are performing well there, although Betty's continues to be our lead horse in terms of volume. Betty's is now number five, up from number seven last quarter. That's not our only success in Illinois, though. Vibations has climbed to the number six brand in beverages and Bubby's to number two in baked goods. Keep in mind that this success was achieved in just over a year in a very mature Illinois market. Nature's Heritage flower hit shelves right after the quarter closed, so it's too early to provide market data. What I can tell you is that the testing of the product has been very strong, and consumer feedback has been terrific. In Massachusetts, we saw modest growth in wholesale in a market that seems to have stabilized for us.

Ryan Crandall
Ryan Crandall
Chief Commercial Officer at MariMed Inc

Our brands continue to have strong penetration in the state with our products in 71% of nearly 400 dispensaries. Our brand share is equally strong. Betty's remains the number one edible in Massachusetts, and our other brands are doing great as well. Bubby's is number three among baked goods, and Vibations is number seven among beverages. In Maryland, we've hit the trifecta with Betty's, Bubby's, and Vibations all number one in their respective categories. For that matter, Betty's remains the number one edible in Delaware as well. Turning to our dispensaries, the way we look at it, we're in a long game. As Jon said, we're doing everything we can to deliver an exceptional customer experience in the face of today's market challenges, and we believe our initiatives across pricing, marketing, and operations are working to offset the impact.

Ryan Crandall
Ryan Crandall
Chief Commercial Officer at MariMed Inc

We're buying smarter, which has enabled more competitive pricing options for our customers, as well as a decrease in days on hand inventory. We've streamlined our labor in strong alignment with customer traffic data, and we've unified and enhanced our customer loyalty program across all our markets. Looking forward, we're excited about some of the positive things that are happening as far as new regulations in some of our markets that should provide us opportunities to grow our retail sales. For instance, Maryland just announced that they're going to allow public cannabis events. Our Annapolis store has a great space to host such events. In Massachusetts, where home delivery has continued to gain traction as an option for our retail customers, a new regulation will enable us to have one driver in our delivery vehicles rather than two.

Ryan Crandall
Ryan Crandall
Chief Commercial Officer at MariMed Inc

We'll be able to put that cost saving into putting another vehicle on the road. I'm also really excited about the innovative new products we're bringing to the market. Our Betty's Eddie's caramel chew that we recently launched in Massachusetts is selling very well. Next up is an entirely new product format for us. In the next few weeks, we're launching a brand that takes advantage of the fast growth of functional mushrooms that we're seeing in the traditional CPG space. It's called Microdose by Nature's Heritage and will come in a convenient pill form that's vegan. Jon has instilled in the company the mantra that we are going to win by becoming the leading consumer packaged goods company in cannabis. That is a highly achievable goal given the performance of our current portfolio.

Ryan Crandall
Ryan Crandall
Chief Commercial Officer at MariMed Inc

There are significant opportunities to continue growing market share as we push the envelope on innovation, marketing, and execution. That concludes my update, and I'll turn the call over to Mario.

Mario Pinho
Mario Pinho
CFO at MariMed Inc

Thank you, Ryan, and good morning, everyone. Last night, we reported first quarter revenue of $38 million, which was flat year on year and decreased sequentially 2.7% from $39 million. The sequential drop was due to an expected seasonal impact, partially offset by one month of revenues from FSC, which we acquired effective March 1. Wholesale gross revenue increased 16% versus the prior year quarter and 4% sequentially, driven by increased market penetration, as Ryan noted. Overall, retail revenue was down 7% versus the prior year period due to the market challenges that Jon and Ryan alluded to earlier. On a gross revenue basis, 44% of our Q1 sales were derived from the wholesale business in keeping with our planned focus on building our brand distribution.

Mario Pinho
Mario Pinho
CFO at MariMed Inc

Over the past four quarters, wholesale share of product revenue has increased from 38% to 44% as we continue to leverage our brands to enter more doors in existing markets and enter new markets. As Jon explained, this is a planned shift in our strategic focus and will naturally dilute margins. We are mitigating the impact through product mix management and SKU rationalization, optimizing supply chain and sourcing, and implementing operational efficiencies and automation. Non-GAAP adjusted gross margin for the first quarter was 41.3%, which was down from 43.8% in the same period last year and 43.3% in the prior quarter. The declining gross margins were primarily driven by price compression along with ramp-up of costs related to our new cultivation facilities in Illinois and our new processing facility in Missouri.

Mario Pinho
Mario Pinho
CFO at MariMed Inc

In Missouri especially, market entry has been slower due to reciprocity challenges in a nascent market where we recognized our first sale in December 2024. The company incurred a net loss of $5.4 million during the quarter. This compares to a net loss of $1.3 million in the same period last year and $8.3 million last quarter. Total operating expenses for the first quarter were $16 million, or 42% of revenue, compared with $14.5 million, or 38% of revenue last year. The increase was due to a one-time write-off of miscellaneous receivables related to our retail business. Operating expenses, excluding intangible amortization, one-time deal costs, and stock-based compensation were $14.9 million compared to $13.9 million in the first quarter of last year. The increase year on year is mainly attributable to the one-time receivable write-off noted previously.

Mario Pinho
Mario Pinho
CFO at MariMed Inc

If we exclude this write-off, approximately 100 basis points of the sequential decrease is due to one month of FSC's operations offset by cost-saving initiatives and further steps to streamline operations we commenced in the latter part of 2024. Adjusted EBITDA in Q1 was $2.6 million, down from the $4.7 million a year ago and $5.9 million in Q4. This decrease was due to lower gross profits converting through to the bottom line and higher compensation and benefit costs associated with higher headcount attributable to new assets in Illinois, Missouri, and Delaware, and the one-time write-off of a receivable balance. In response, disciplined expense management remains a top priority as we navigate today's challenging environment, and we continue to look for opportunities to reduce our cost structure throughout the company.

Mario Pinho
Mario Pinho
CFO at MariMed Inc

Turning to the balance sheet and cash flow, we maintained a strong balance sheet, ending the quarter with $7.2 million in cash and cash equivalents and $2.7 million in working capital. We had no significant capital expenditures during the quarter as major buildouts were completed by the end of 2024. We generated $1.3 million in cash flow from operations versus the $3.2 million in the same period last year. Turning now to Q2, based on our visibility today, we anticipate an increase in second quarter revenue to be in the high single digits compared to Q1. We anticipate the increase to be driven by a full quarter of FSC revenues, modest contributions from our promotional activities, and continued wholesale door ads. At the same time, we anticipate continued softness in retail. That concludes our financial review. I will now turn the call over to Jon for his concluding remarks.

Jon Levine
Jon Levine
CEO and President at MariMed Inc

Thank you, Mario. Before turning the call over to the operator, I want to address our shareholders. Like our shareholders, we are frustrated that the public markets continue to lag behind the intrinsic value of MariMed. It's not a matter of if; it's only a matter of when that turns around. This is a long game, and we've built a very strong foundation to position the company as a thriving industry leader for a long time to come. It's not hyperbole when I say we're driving towards building the best CPG company in cannabis, and our innovation will continue to drive new brands to meet market opportunities. The best days for MariMed are in front of us. Finally, I'd like to thank our MariMed employees for their dedication to improve the lives of our patients and customers every day. Operator, open the lines for questions.

Operator

Thank you. If you would like to ask a question, please press star one on your telephone keypad now. You will be placed into the queue in the order received. Please be prepared to ask your question when prompted. Once again, if you have a question, please press star one on your phone now. One moment while we prepare our Q&A roster. Your first question comes from the line of Andrew Semple from Ventum Financial. Your line is now open.

Andrew Semple
Andrew Semple
Equity Research Analyst at Ventum Financial

Good morning. Thanks for taking my question. First one, just a housekeeping item. In the prepared remarks, you mentioned a revenue increase in the high single digits in the second quarter. I just want to clarify whether that's on a quarter-on-quarter basis or a year-over-year basis.

Mario Pinho
Mario Pinho
CFO at MariMed Inc

Hi, Andrew. It's Mario. It's a quarter-over-quarter basis.

Andrew Semple
Andrew Semple
Equity Research Analyst at Ventum Financial

Great.

Mario Pinho
Mario Pinho
CFO at MariMed Inc

Most of the driver of that. Sorry?

Andrew Semple
Andrew Semple
Equity Research Analyst at Ventum Financial

Oh, I said great. That's helpful.

Mario Pinho
Mario Pinho
CFO at MariMed Inc

Okay.

Andrew Semple
Andrew Semple
Equity Research Analyst at Ventum Financial

I'll move on. Latest expectations in Delaware, I'd love to hear what you're hearing from that state in terms of first adult use sales in that market and when we might expect to see that launch.

Jon Levine
Jon Levine
CEO and President at MariMed Inc

Good morning, Andrew. Thank you for joining the call. Thank you for the question. Delaware has finally found a lead of the cannabis program, and we are told it could be a timing of anywhere from 60 to 120 days before we see the first rec store open.

Andrew Semple
Andrew Semple
Equity Research Analyst at Ventum Financial

Great. Just on the bad debt expense in the quarter, the receivables balance that was written off, maybe just would appreciate some more color into that. Whether you think that's going to be a one-time item for the year or given some of the balance sheet challenges we're seeing across the industry, whether there's the risk that that might be something we could see again later in the year. Just want to get some thoughts around that and how you're managing that risk.

Mario Pinho
Mario Pinho
CFO at MariMed Inc

Hi, Andrew. It's Mario here. Yeah. That is a one-time item. I just want to clarify it does not relate to our trade receivables. It relates to a receivable from a vendor that we had to put a reserve up against. We're obviously pursuing all actions to collect the funds, and I think we ultimately will prevail. For right now, we've put a reserve up against that balance.

Andrew Semple
Andrew Semple
Equity Research Analyst at Ventum Financial

Great. That's it for me. I'll get back into queue. Thanks again.

Operator

Your next question is from the line of Pablo Zuanic from Zuanic & Associates. Please ask your question.

Pablo Zuanic
Managing Partner at Zuanic & Associates

Thank you. Good morning, everyone. Look, the first question was on the area of innovation. You talked about these new hemp products. I do not know how much you can share with us right now, but are we talking about hemp drinks? Are we talking about Betty's hemp-derived gummies? If you can give more color on the products we are thinking about and the distribution, just e-commerce through your own dispensaries only, but also through C-stores, gas stations, and other outlets. By the same token, same question in terms of Microdose, very interesting product. You said functional mushrooms, so we are not talking about psychedelics, I suppose. How wide distribution? I mean, could you sell at Whole Foods and other places, or is this just something you are going to sell at your dispensaries only? Thanks.

Jon Levine
Jon Levine
CEO and President at MariMed Inc

Good morning, Pablo. This is Jon. Thank you for joining the call. Yes, what I stated in the reading was that I was making the mention that we're looking at all aspects to grow the business as our brands are very successful and that hemp is another direction for adding additional revenue. We're looking at all aspects. Our brand recognition is already there with our brands. We are looking at beverage and other lines, but we haven't made the final decision on what we're doing fully in the hemp yet. We're looking at making sure we make the decision that's best for the company without hurting our cash flow or earnings. As far as the Microdose, I'm going to let Ryan speak about that.

Ryan Crandall
Ryan Crandall
Chief Commercial Officer at MariMed Inc

Sure. Thanks for the question, Pablo. Very excited about Microdose. Microdose will not just be in panacea stores, so that will be a widely distributed product across all our states. Very excited to bring Microdose to market. We feel it is an innovative product in the market. 1906 has had its day and done a really good job of showing that people will consume cannabis through a pill form. I think we're innovating beyond what 1906 has done here. We're really grabbing on to what we see as a trend in CPG around functional mushrooms, bringing effects-based functional mushrooms to bear within the product. It's a vegan product that's calorie-free. We feel really confident that it's made really well and that it's going to perform really well. Yeah. Actually, it hit shelves this weekend, actually, in Massachusetts.

Pablo Zuanic
Managing Partner at Zuanic & Associates

Right. When you said, Ryan, in all your states, there would still be in dispensaries, right? Third-party dispensaries, or are you thinking of other non-cannabis outlets?

Ryan Crandall
Ryan Crandall
Chief Commercial Officer at MariMed Inc

Pablo, I think that plays into the whole hemp strategy that Jon mentioned. That is still under evaluation. I think the real headline there is we're looking at every opportunity to expand our brands.

Pablo Zuanic
Managing Partner at Zuanic & Associates

Right. Okay. Understood. On the same topic, I think you've mentioned the opportunity for licensing your brands, especially Betty's. New York, it's a fast-growing market. How do you think about that? Do you always want to have control of the supply chain and control your operation in the markets that you operate? For example, with New York, licensing to someone there, Betty's, would that make sense? How do you think about that?

Jon Levine
Jon Levine
CEO and President at MariMed Inc

Pablo, good question. Thank you very much for asking. We have been working with other vendors in New York. We have a license that we applied for well over a year ago, still waiting for word on that. In the meantime, we are in discussions with a few groups in New York and other states to bring our Betty's and our other products to that state or to other states. That's just another avenue for additional revenue. We're not against finding it, but it's finding the right partner that will put the dedication and time into doing what our SOPs require.

Pablo Zuanic
Managing Partner at Zuanic & Associates

Okay. Thank you. Look, just two last questions. One, just an update on the second Maryland store. I think you closed on the acquisition. Is it open? Are you going to move the store? How is it doing? Can you share any color on that? Then separately, maybe try to help us quantify the upside from Delaware, right? Your estimates of the current size of the medical market. I think there are only seven stores. It will take a while for new licensees to open stores. That could be a great opportunity there. Just any tools you can give us to quantify the upside from Delaware. I realize it is a small state, but only seven stores. That should mean a relevant upside. Thank you.

Jon Levine
Jon Levine
CEO and President at MariMed Inc

Our Upper Marlborough store in Maryland continues to grow every month, and we're very excited about how well it's doing. We continue to see positives there. In Delaware, yes, there presently is only seven stores, but they have already issued several adult use licenses to social equity people that have started to build out their locations, even though there's a delay on the final licensing. We're hopeful that our wholesale business will be able to start shipping earlier than later. As I said, you're looking at 60 to 120 days before they'll have that up and running. We are ready. We're excited and ready to go with all of our brands, plus some additional brands that the First State had already down there. Yeah.

Ryan Crandall
Ryan Crandall
Chief Commercial Officer at MariMed Inc

Pablo, just to dovetail on Jon's answer, we have relationships with all open stores today, and our team is actively creating relationships with all the stores to open, doing that ahead of time. We are well-positioned when those stores do open.

Pablo Zuanic
Managing Partner at Zuanic & Associates

That's great. Thank you.

Operator

As a reminder, if you'd like to ask a question, please press star and the number one on your touch-tone phone. Your next question comes from the line of Joe Gomes from NOBLE Capital. Please ask your question.

Joe Gomes
Joe Gomes
Senior Research Analyst at NOBLE Capital

Good morning. Wanted to start off, you mentioned that Missouri seems to have been a little bit more challenging than expected, and was wondering if you could provide a little more color and detail there.

Ryan Crandall
Ryan Crandall
Chief Commercial Officer at MariMed Inc

Sure, Joe. Thank you for the question. This is Ryan Crandall. I would say Missouri is a market that does not have a ton of companies that operate outside of Missouri. They are localized operators. Those localized operators, as that market has grown, have created a network amongst themselves that they buy and sell products from each other. They have full menus. As new folks come into that market, there is a—I do not want to say a protected menu at each location, but there is a good amount of breakthrough that has to happen. You are not just breaking onto their shelves. You are breaking into a category that they are already sharing with someone else. I think some of that, what you hear, reciprocity in the cannabis markets, I think it is very strong in Missouri.

Ryan Crandall
Ryan Crandall
Chief Commercial Officer at MariMed Inc

I mean, I do think we see that ultimately great brands and great products do win the day. We are getting into more and more stores every month. That is the name of the game. Once we get into the doors, how do we expand, and then how do we support the highest level of velocity that we can? We have great teams, great processes to do all that. I'm very confident that we're going to be able to continue to grow in Missouri.

Joe Gomes
Joe Gomes
Senior Research Analyst at NOBLE Capital

Okay. Thanks for that color. Then just looking at the income statement, marketing and promotion was down pretty significantly, spending year-over-year. I was just wondering, was there something unusual in the first quarter of last year, or what is behind the decline there in the marketing and promotion spend?

Mario Pinho
Mario Pinho
CFO at MariMed Inc

Joe, it's Mario here. I guess as we're looking at our operating expenses, obviously, we're being a lot more thoughtful and smart in terms of where we're spending our dollars. That's purely just a reduction in more of our programmatic marketing. We're focusing more on localized marketing, and that's purely why you see the decrease in the dollars there.

Joe Gomes
Joe Gomes
Senior Research Analyst at NOBLE Capital

Okay. Let me see. I think I have one more here. I do not talk too much. Oh, in Ohio, I know you had talked about possibly getting another retail location. Obviously, you would like to get the full integrated operations there. I wonder if you can give us a little more of an update on where things stand in Ohio.

Jon Levine
Jon Levine
CEO and President at MariMed Inc

Hey, Joe. Jon Levine, thank you for joining the call today. In Ohio, we have been looking for real estate, and it has to be in an area where you can get support from the local community. With all the setback requirements and everything else, and also whether we buy or we lease, those things come into making it a little bit difficult because of all the limitations with cannabis still, even with local government saying yes and no, but more importantly, the bank that we get our mortgages from, making sure that they're going to be fully comfortable with the valuation. We do have several people looking, and we've looked at a couple, lost a few bids, but we're hopeful that we can get something done before the end of the year.

Joe Gomes
Joe Gomes
Senior Research Analyst at NOBLE Capital

Great. Thanks for that. I'll get back in queue.

Operator

There are no further questions at this time. This concludes today's conference call. Thank you for your attendance.

Executives
    • Ryan Crandall
      Ryan Crandall
      Chief Commercial Officer
    • Jon Levine
      Jon Levine
      CEO and President
    • Kevin Compagna
      Kevin Compagna
      VP of North America Sales Wholesale and Licensing
    • Mario Pinho
      Mario Pinho
      CFO
Analysts
    • Pablo Zuanic
      Managing Partner at Zuanic & Associates
    • Joe Gomes
      Senior Research Analyst at NOBLE Capital
    • Andrew Semple
      Equity Research Analyst at Ventum Financial
Powered by Quartr